Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity

• DOI: 10.1136/jitc-2022-005718
• Publication Date: 2023-01-02T15:50:14Z
• Authors: Marc Pfefferlé; Irina L Dubach; Raphael M Buzzi; Elena Dürst; Nadja Schulthess-...; Livio Baselgia; Kerstin Hansen; Larissa Imhof; Sandra Koernig; Didier Le Roy; Thierry Roger; Rok Humar; Dominik J Schaer; Florence Vallelian
• Keywords: Reprogramming; Cancer Immunotherapy

Agonistic anti-CD40 monoclonal antibodies (mAbs) have emerged as promising immunotherapeutic compounds with impressive antitumor effects in mouse models. However, preclinical and clinical studies faced dose-limiting toxicities mediated by necroinflammatory liver disease. An effective prophylactic treatment for immune-related adverse events that does not suppress specific immunity remains to be found.